The critical role of the class III histone deacetylase SIRT2 in stabilizing N-Myc oncoprotein. Cancer is the commonest cause of death from disease in children. Neuroblastoma is the commonest solid tumor in early childhood. This project will investigate the critical roles of SIRT2 protein in increasing the expression of N-Myc oncoprotein and consequently inducing neuroblastoma, and SIRT2 inhibitors as anticancer agents.
Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.
Molecular hallmarks of androgen receptor targeting in prostate cancer. There is a critical need in oncology drug development for better biomarkers of response to prostate cancer therapies, clinically to assist with treatment decision making, and pre-clinically to facilitate translation of emerging agents into clinical practice. Using a unique explant culture model, this project will identify protein and lipid markers that can be used to accurately and reliably assess response to androgen recepto ....Molecular hallmarks of androgen receptor targeting in prostate cancer. There is a critical need in oncology drug development for better biomarkers of response to prostate cancer therapies, clinically to assist with treatment decision making, and pre-clinically to facilitate translation of emerging agents into clinical practice. Using a unique explant culture model, this project will identify protein and lipid markers that can be used to accurately and reliably assess response to androgen receptor (AR)-targeting therapies in human prostate tumours. The identification and functional assessment of these biomarkers will identify those that can be used as surrogate endpoints in clinical trials, facilitate earlier approval of investigational agents and lead to improved options for therapeutic management of prostate cancer.Read moreRead less
Transient Tissue ‘priming’ Via FAK Inhibition To Impair Pancreatic Cancer Progression And Improve Sensitivity To Gemcitabine/Abraxane
Funder
National Health and Medical Research Council
Funding Amount
$643,848.00
Summary
The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE110100239
Funder
Australian Research Council
Funding Amount
$480,000.00
Summary
Small biological molecule tissue imaging mass spectrometry facility for Western Australia for spatial metabolomics and lipidomics. This tissue imaging facility for Western Australia will provide researchers with access to much needed instrumentation. The facility will support major research efforts in key disciplines, including agriculture and animal science, fisheries and medical science.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE100100217
Funder
Australian Research Council
Funding Amount
$450,000.00
Summary
In-Vivo Multispectral and X-ray Micro-CT Imaging: Founding a Western Australian small animal imaging core facility. The Western Australian Small Animal Imaging facility will provide wide access for the West Australian research community to a multimodality functional and dynamic core bioimaging facility to characterise in-vivo animal models, including extensive postgraduate research training. Wide-ranging research outcomes of national and community benefit include imaging tumour development, bone ....In-Vivo Multispectral and X-ray Micro-CT Imaging: Founding a Western Australian small animal imaging core facility. The Western Australian Small Animal Imaging facility will provide wide access for the West Australian research community to a multimodality functional and dynamic core bioimaging facility to characterise in-vivo animal models, including extensive postgraduate research training. Wide-ranging research outcomes of national and community benefit include imaging tumour development, bone metabolism (osteoporosis), neural function (Alzheimer's disease) and regeneration, and infection mechanisms in live animals, which will result in improvements in human health. Imaging and monitoring coral growth, fish age, and soil structure will improve the economics and sustainability of Australia's marine ecosystems and agricultural food production.Read moreRead less